(O-23) EFFECTIVENESS OF COMPREHENSIVE TREATMENT FOR ERECTILE DYSFUNCTION WITH MEDICATION AND SHOCKWAVE THERAPY: A REAL-LIFE STUDY

Abstract

Abstract Objective To evaluate the effectiveness of adding shockwave therapy to pharmacological treatment in a cohort of men with erectile dysfunction in Colombia and Peru. Methods Observational cohort study. Patient records from those treated for erectile dysfunction in 2022 were reviewed. Patients over 18 years old, without other sexual dysfunctions were included. Changes in the IIEF-EF questionnaire score and the proportion of patients achieving penetration capability (EHS >2) after treatment were assessed. Results 317 patients met the criteria and were included in the analysis. 150 received medication only (group 1) and 167 received shockwave therapy + medication (group 2). The median duration of treatment was 4.8 months for group 1 and 5.6 months for group 2. The initial IIEF-EF score for group 1 was 15.8 (+/-5.4) and the average increase at the end of treatment was 7.35 (+/-5.4) points. In group 2, the initial IIEF-EF was 14.7 (+/-4.9) and the average increase was 7.47 (+/-5.8). At the end of treatment, 39.3% of patients in group 1 and 42.5% in group 2 reported no ED according to the IIEF-EF score. The proportion of patients who could not achieve penetration (EHS <=2) before treatment and achieved sufficient rigidity for penetration (EHS >2) after treatment was 85% in group 1 and 94% in group 2. Conclusions The additional use of shockwave therapy improves the outcomes of pharmacological treatment in patients with ED. Financing Boston Medical Group.